Status:
ACTIVE_NOT_RECRUITING
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Lead Sponsor:
Dana-Farber Cancer Institute
Conditions:
Multiple Myeloma
Waldenstrom's Macroglobulinemia
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to obtain bone marrow and peripheral blood samples, along with clinical data from patients with Multiple Myeloma (MM), Waldenstrom's Macroglobulinemia (WM), Smoldering MM,...
Detailed Description
* Participants will be asked to complete a medical survey which includes demographics, diagnosis, and treatment history, medical history, lab results and symptoms experienced. * Participants will then...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Any individual diagnosed with Multiple Myeloma, Waldenstrom Macroglobulinemia, MGUS, smoldering MM or other lymphoplasmacytic lymphomas
- Signed informed consent
- 18 years of age or older
Exclusion
Key Trial Info
Start Date :
December 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2026
Estimated Enrollment :
656 Patients enrolled
Trial Details
Trial ID
NCT01177527
Start Date
December 1 2009
End Date
January 1 2026
Last Update
November 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115